Allergan PLC. Company Profile (NYSE:AGN)

About Allergan PLC. (NYSE:AGN)

Allergan PLC. logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:AGN
  • CUSIP: 01849010
  • Web:
  • Market Cap: $67.7505 billion
  • Outstanding Shares: 334,306,000
Average Prices:
  • 50 Day Moving Avg: $229.79
  • 200 Day Moving Avg: $236.07
  • 52 Week Range: $184.50 - $256.80
  • Trailing P/E Ratio: 6.24
  • Foreward P/E Ratio: 11.41
  • P/E Growth: 0.96
Sales & Book Value:
  • Annual Revenue: $15.07 billion
  • Price / Sales: 4.54
  • Book Value: $210.39 per share
  • Price / Book: 0.97
  • Annual Dividend: $2.80
  • Dividend Yield: 1.4%
  • EBIDTA: $6.15 billion
  • Net Margins: 79.17%
  • Return on Equity: 7.37%
  • Return on Assets: 4.17%
  • Debt-to-Equity Ratio: 0.38%
  • Current Ratio: 1.21%
  • Quick Ratio: 1.10%
  • Average Volume: 2.05 million shs.
  • Beta: 1.18
  • Short Ratio: 3.43

Frequently Asked Questions for Allergan PLC. (NYSE:AGN)

What is Allergan PLC.'s stock symbol?

Allergan PLC. trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan PLC. pay dividends? What is the dividend yield for Allergan PLC.?

Allergan PLC. declared a quarterly dividend on Wednesday, August 2nd. Investors of record on Friday, August 18th will be paid a dividend of $0.70 per share on Friday, September 15th. This represents a $2.80 annualized dividend and a yield of 1.37%. The ex-dividend date is Wednesday, August 16th. View Allergan PLC.'s Dividend History.

How were Allergan PLC.'s earnings last quarter?

Allergan PLC. (NYSE:AGN) released its earnings results on Thursday, August, 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. The company earned $4.01 billion during the quarter, compared to analysts' expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. Allergan PLC.'s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.35 EPS. View Allergan PLC.'s Earnings History.

When will Allergan PLC. make its next earnings announcement?

Allergan PLC. is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Allergan PLC..

What guidance has Allergan PLC. issued on next quarter's earnings?

Allergan PLC. updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $16.05-16.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.08. The company issued revenue guidance of $15.85-16.05 billion, compared to the consensus revenue estimate of $15.81 billion.

Where is Allergan PLC.'s stock going? Where will Allergan PLC.'s stock price be in 2017?

18 analysts have issued twelve-month price objectives for Allergan PLC.'s shares. Their forecasts range from $228.00 to $400.00. On average, they expect Allergan PLC.'s share price to reach $275.24 in the next year. View Analyst Ratings for Allergan PLC..

What are analysts saying about Allergan PLC. stock?

Here are some recent quotes from research analysts about Allergan PLC. stock:

  • 1. Cantor Fitzgerald analysts commented, "Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak." (9/22/2017)
  • 2. According to Zacks Investment Research, "Allergan is reshaping its portfolio through strategic acquisitions. Following the closure of the Teva deal, Allergan can now focus on the branded segment and is using the proceeds to buy back shares, pay down debt and pursue additional deals. Key products like Botox and Linzess and new products are supporting sales growth. Allergan’s share price has outperformed the broader industry, so far this year. It also boasts a strong pipeline. Biosimilars also represent significant opportunity. While we remain optimistic about the company’s growth prospects, it is facing generic threat for Namenda IR as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also new competition for key growth drivers, Restasis and Linzess, is an investor concern. Estimates have gone up ahead of the Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters." (7/11/2017)
  • 3. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)

Who are some of Allergan PLC.'s key competitors?

Who owns Allergan PLC. stock?

Allergan PLC.'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.80%), State Street Corp (4.66%), Northern Trust Corp (1.34%), Bank of New York Mellon Corp (1.03%), TIAA CREF Investment Management LLC (0.90%) and Paulson & CO. Inc. (0.81%). Company insiders that own Allergan PLC. stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan PLC..

Who sold Allergan PLC. stock? Who is selling Allergan PLC. stock?

Allergan PLC.'s stock was sold by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Farallon Capital Management LLC, State Street Corp, American Century Companies Inc., Renaissance Technologies LLC, Paulson & CO. Inc., Epoch Investment Partners Inc. and Bank of New York Mellon Corp. Company insiders that have sold Allergan PLC. stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..

Who bought Allergan PLC. stock? Who is buying Allergan PLC. stock?

Allergan PLC.'s stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Northern Trust Corp, Eaton Vance Management, Harbour Capital Advisors LLC, Balyasny Asset Management LLC, HealthCor Management L.P., Iridian Asset Management LLC CT and CI Investments Inc.. Company insiders that have bought Allergan PLC. stock in the last two years include Brent L Saunders and Maria Teresa Hilado. View Insider Buying and Selling for Allergan PLC..

How do I buy Allergan PLC. stock?

Shares of Allergan PLC. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan PLC.'s stock price today?

One share of Allergan PLC. stock can currently be purchased for approximately $204.65.

MarketBeat Community Rating for Allergan PLC. (NYSE AGN)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  864 (Vote Outperform)
Underperform Votes:  379 (Vote Underperform)
Total Votes:  1,243
MarketBeat's community ratings are surveys of what our community members think about Allergan PLC. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Allergan PLC. (NYSE:AGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $275.24 (34.49% upside)

Analysts' Ratings History for Allergan PLC. (NYSE:AGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/22/2017Cantor FitzgeraldReiterated RatingHold$231.00LowView Rating Details
9/20/2017Citigroup Inc.Reiterated RatingBuy$280.00LowView Rating Details
9/20/2017Morgan StanleyDowngradeOverweight -> Equal Weight$284.00 -> $228.00MediumView Rating Details
9/12/2017Deutsche Bank AGReiterated RatingBuy$262.00LowView Rating Details
9/11/2017Wells Fargo & CompanyReiterated RatingOutperformLowView Rating Details
9/6/2017Royal Bank Of CanadaReiterated RatingBuy$285.00MediumView Rating Details
8/29/2017Cowen and CompanyReiterated RatingOutperform$400.00LowView Rating Details
8/14/2017ArgusReiterated RatingBuy$280.00LowView Rating Details
8/5/2017Credit Suisse GroupSet Price TargetBuy$286.00 -> $288.00LowView Rating Details
8/2/2017MizuhoReiterated RatingBuy$267.00LowView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$231.00LowView Rating Details
5/25/2017Sanford C. BernsteinReiterated RatingOutperformLowView Rating Details
5/10/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$262.00HighView Rating Details
2/9/2017Leerink SwannBoost Price TargetBuy$280.00N/AView Rating Details
12/23/2016Bank of America CorporationReiterated RatingBuy$280.00N/AView Rating Details
12/5/2016J P Morgan Chase & CoSet Price TargetBuy$300.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
10/31/2016Barclays PLCReiterated RatingEqual Weight$250.00N/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James Financial, Inc.Lower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for Allergan PLC. (NYSE:AGN)
Earnings by Quarter for Allergan PLC. (NYSE:AGN)
Earnings History by Quarter for Allergan PLC. (NYSE AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017$4.19N/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.95 billion$4.01 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan PLC. (NYSE:AGN)
2017 EPS Consensus Estimate: $16.25
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$3.33$3.55$3.44
Q2 20172$4.00$4.07$4.04
Q3 20173$4.09$4.16$4.14
Q4 20173$4.52$4.72$4.64
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan PLC. (NYSE:AGN)
Most Recent Dividend:9/15/2017
Annual Dividend:$2.80
Dividend Yield:1.37%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:9.95% (Trailing 12 Months of Earnings)
17.25% (Based on This Year's Estimates)
15.62% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Allergan PLC. (NYSE:AGN)

Dividend History by Quarter for Allergan PLC. (NYSE AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Allergan PLC. (NYSE:AGN)
Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 82.02%
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Allergan PLC. (NYSE:AGN)
Latest Headlines for Allergan PLC. (NYSE:AGN)
DateHeadline logoAllergan PLC.'s (AGN) Hold Rating Reaffirmed at Cantor Fitzgerald - September 22 at 11:30 AM logoAllergan PLC. (AGN) Stock Rating Lowered by Morgan Stanley - September 21 at 12:38 AM logoAllergan PLC.'s (AGN) "Buy" Rating Reaffirmed at Citigroup Inc. - September 20 at 5:10 PM logoShould Value Investors Consider Allergan plc (AGN) Stock Now? - September 20 at 3:30 PM logoApple Likes the Patent ‘Death Squad.’ Allergan Pays to Avoid It - September 20 at 3:30 PM logoAllergan: Just How Far Will Big Pharma Go To Protect Its Patents? - September 20 at 3:30 PM logo[$$] States Push Ahead With Investigation Into Opioid Painkillers - September 19 at 8:40 PM logoWhy Allergan Could Be A $300 Stock - September 18 at 4:01 PM logoAMD leading IQ100 top gainers - September 18 at 4:01 PM logoSenator attacks Allergan's sovereign-immunity tactic on Restasis - Seeking Alpha - September 15 at 8:59 PM logoAmgen/Allergan's Avastin Biosimilar Secures FDA Approval - September 15 at 3:56 PM logoU.S. senator slams Allergan tribal patent deal - September 15 at 3:56 PM logoU.S. senator slams Allergan patent deal with Native-American tribe - September 15 at 3:56 PM logoAmgen (AMGN), Allergan (AGN) Confirm FDA Approval of MVASI For Treatment of Five Types of Cancer - - September 15 at 1:53 AM logoAstraZeneca Sells Remaining Rights to its Anaesthetics Drugs - September 14 at 3:46 PM logoThese party drugs could become the answer for clinically ... - September 14 at 3:46 PM logoFDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer - September 14 at 3:46 PM logoAmgen and Allergan say FDA has approved biosimilar of Roche's Avastin - September 14 at 3:46 PM logoWhy pharma companies are scared of Bernie’s Medicare for All plan - September 14 at 2:51 AM logoCramer's lightning round: Allergan's in a torturous situation - September 13 at 4:42 PM logoAllergan Pulls A Fast One - Seeking Alpha - September 12 at 8:49 PM logoAllergan Launches New Brilliant Distinctions® Patient Loyalty Program - September 12 at 8:49 PM logoMylan says Allergan misusing tribal sovereignty in patent dispute - September 12 at 8:49 PM logoTech entity has tribal patent deal similar to Allergan's - September 12 at 8:49 PM logoDeutsche Bank AG Trims Allergan PLC. (AGN) Target Price to $262.00 - September 12 at 9:30 AM logoTeva's New CEO Brings This Secret Weapon - September 11 at 9:26 PM logoAllergan Patent Deal Isn't Just Unusual. It's Ugly. - September 11 at 9:26 PM logoThe Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts - September 11 at 9:26 PM logoSovereign Immunity and Public Hangings - September 11 at 9:26 PM logoCramer's lightning round: Allergan's in a torturous situation - September 11 at 9:26 PM logoU.S. tribal patent deal could have big impact on generic drug market - September 11 at 9:26 PM logoIrma to Bring Droves to Aisles of Home Depot; Teva Reveals Savior CEO - ICYMI - September 11 at 9:26 PM logoAllergan PLC. (AGN) Rating Reiterated by Wells Fargo & Company - September 11 at 2:32 PM logoHere's Why Allergan Stock Might Be an Incredible Bargain After Dropping 9.9% in August - September 11 at 11:35 AM logoCasinos Aren’t Enough as Native Tribe Makes Deal on Drug Patents - September 9 at 3:27 PM logo$4.05 Billion in Sales Expected for Allergan PLC. (AGN) This Quarter - September 9 at 3:44 AM logoAllergan $13.75 mln agreement with Saint Regis Mohawk Tribe a play to protect key dry eye product - MarketWatch - September 9 at 2:02 AM logoAllergan Shares Rise on Novel Patent Pact for Restasis - September 8 at 9:00 PM logoAllergan (AGN) and Saint Regis Mohawk Tribe Announce Agreement on RESTASIS Patents - September 8 at 3:59 PM logo[$$] Merck Tops JNJ, Allergan - September 8 at 3:59 PM logoAllergan and Saint Regis Mohawk Tribe Announce Agreements Regarding RESTASIS® Patents - September 8 at 3:59 PM logoA Native American Tribe, a Drugmaker and an Unusual Patent Plan - September 8 at 3:59 PM logoAllergan reaches agreement regarding RESTASIS patents - September 8 at 3:58 PM logoAllergan $13.75 mln agreement with Saint Regis Mohawk Tribe a play to protect key dry eye product - September 8 at 3:58 PM logo[$$] Allergan Partners With Indian Tribe to Protect Drug Patents - September 8 at 3:58 PM logo[$$] Allergan Partners With Indian Tribe to Protect Drug Patents - September 8 at 3:58 PM logoForget casinos: This Native American tribe is doing business in pharma patents - September 8 at 3:58 PM logoForget casinos: This Native American tribe is doing business in pharma patents - September 8 at 3:58 PM logoAllergan pays Mohawk Tribe to protect patents from challenges - September 8 at 3:58 PM logoAllergan pays Mohawk Tribe to protect patents from challenges - September 8 at 3:58 PM



Allergan PLC. (AGN) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff